Survival was not significantly different between BRCA1, BRCA2 and non-BRCA carriers on enhanced screening (Fig. 2d) with 20-year breast cancer specific survival particularly good in 60 BRCA1 carriers at 91.5% (78.5–96.8) compared to 59 BRCA2 at 85.1% (64.1–94.3) and 275 non-BRCA 84.7% (76.5–90.3). This evidence concerns the gene BRCA2 and breast cancer.